Eko Health announces large-scale deployment of AI heart disease detection technology
Press releases may be edited for formatting or style
| November 06, 2023
EMERYVILLE, Calif. , Nov. 6, 2023 /PRNewswire/ -- Eko Health, Inc. (Eko), a leader in AI technology for heart and lung disease detection, today announced the regulatory approval (UKCA marking) and frontline deployment of the company's AI-enabled technology in the United Kingdom (UK). TRICORDER, a National Institute for Health and Care Research (NIHR) funded implementation program led by researchers at Imperial College London, will deploy Eko's AI-enabled technology (marketed in the U.S. as SENSORA™) to primary care practices across the UK. This novel implementation will assist clinicians in their evaluation of heart failure (HF), valvular heart disease (VHD), and atrial fibrillation (AFib), ultimately serving as an AI-enabled clinical decision support tool for echocardiogram referrals.
The team at Imperial College London will deploy Eko's technology to 100 General Practitioner (GP) practices across the UK. Patients visiting their GP will receive a brief, non-invasive cardiac exam. The exam uses an Eko digital stethoscope and app powered by the company's AI. When Eko's AI detects possible signs of cardiac disease, the GP can rapidly initiate further tests and potentially life-saving treatments. The current gold standard to detect heart failure is a blood test (NT-proBNP) that when ordered alone, initiates a long pathway that often fails to achieve early diagnosis and treatment in those who need it most. This novel deployment can potentially improve heart disease outcomes for millions of people in communities across the UK.
"Heart failure admission alone costs the UK over £2 billion annually, and an unacceptable 80% of these diagnoses are made during emergency admissions," said Dr. Nicholas Peters, Professor of Cardiology, Imperial College London and Imperial College Healthcare NHS Trust, and the clinical-academic implementation team lead. Co-investigators Dr. Patrik Bächtiger and Dr. Mihir Kelshiker commented, "TRICORDER is a system-wide implementation of Eko's clinically effective AI technology. Implementing this tool in primary care could save the health payer system £2,400 per patient, eliminating the potential need for an emergency room visit."
"This deployment around the UK of our AI-enabled heart disease detection technology demonstrates the need for accurate and early heart disease detection," said Connor Landgraf, Co-founder and CEO of Eko Health. "We're proud to partner with leading academic institutions such as Imperial College London to validate the clinical utility and positive impact our technology has on the lives of millions of patients."
You Must Be Logged In To Post A Comment
Registration is Free and Easy.
Enjoy the benefits of The World's Leading New & Used Medical Equipment Marketplace.